IO Biotech is trialing Cylembio in combination with Merck's anti-PD-1 therapy.
5 reports, 2 independent
Updated Sep 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 4
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
IO Biotech is trialing Cylembio in combination with Merck's anti-PD-1 therapy.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- IO Biotech compared its vaccine to Merck & Co.'s Keytruda.Sub-event
IO Biotech and Merck are collaborating on a drug trial for anti-PD-1 therapy.1 source
IO Biotech plans to discuss vaccine data with the FDA in combination with Merck's therapy.1 source
IO Biotech plans to meet with the FDA regarding its trial using Merck's anti-PD-1 therapy.1 source
Keep exploring
The entities involved
-
Mai-Britt Zocca
researcher
Nothing else this week.
-
Merck
public company in Indonesia
Coverage
Newest first; wire copies grouped- GlobeNewswireIO Biotech Announces Participation in Upcoming Investor Conferences NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel
- GlobeNewswireIO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® pl
- Clinical Trials ArenaIO Biotech to pursue cancer vaccine approval despite Phase III miss IO Biotech’s lead cancer vaccine asset, Cylembio (imsapepimut and etimupepimut, adjuvant), has narrowly missed its primary endpoint
- GlobeNewswireIO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melano
- GlobeNewswireIO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma NEW YORK, Aug.